Alector的动态

#RareDiseaseDay at AskBio is about honoring the journeys of those impacted. Today provides us with an opportunity to pause and highlight what matters most: patients, caregivers, and their loved ones. With this in mind, we invite you to learn more about Haley, who lives with #PompeDisease.? #AskBio #genetherapy

We know that primary health care care is one of the only parts of the health system in which investments routinely and predictably result in improved equity for all people, especially the most vulnerable. But under fee-for-service payment, the value of clinical work = time and intensity. This leaves behind - Patient relationships - Team-based care - Care coordination - Time for diagnosis These are precisely the things that make?#PrimaryCare?so powerful. In his presentation,?Asaf Bitton?discussed strategies for aligning payment with the value #PrimaryCare provides.

On this day, we reaffirm our commitment to advancing research, innovation, and #precisiononcology. Every breakthrough brings us closer to better outcomes for #patients. #PrecisionOncology #Innovation #BreastCancerAwarenessMonth #HER2DX #DNADX #TNBCDX?

Dogs Without Borders from VML Health has been featured on Fast Company’s 2024 World Changing Ideas list! People living in remote areas only make the journey to see a doctor when they experience symptoms. We came up with a game-changing solution — turn rescue dogs into miracle workers, training them to catch cancer before it progresses in places that lack basic medical services. Learn more via the link below! #VMLHealth #FCWorldChangingIdeas #HealthcareMarketing #PharmaMarketing

???? Hey there, fellow #EMS, #Paramedics, #Firefighters, and #EMTs! ?? I can’t tell you how excited I am to invite you to come hang out with me at booth 14 during the #GEMSAleadershipconference2024. We’re going to dive into some really cool stuff that’s changing the game in #prehospitalpatientcare. ?? Here’s a sneak peek of what we’ll chat about: ? How the HAMILTONT1 isn’t just improving #patientcare but creating significant impacts on provider #workflows, while reducing #workload, and reducing #cognitive load. ?? ? How #volumetriccapnography is revolutionizing whole blood programs. Let’s make every #drop count ?? ? The secrets behind setting #optimalPEEP for better patient outcomes ?? ? The game-changer that is automated #CPRventilation ???? ? And the wonders of #adaptivesupportventilation, #NIV, #CPAP, and #BiPAP in treating a wide range of patient needs ??? But wait, there’s more! I’ll walk you through how incredibly easy it is to set up the #HAMILTONT1 with just a patient’s #gender and #height. It’s like magic – suddenly, you’ve got the Ideal Body Weight (IBW) figured out, and we’re talking about #lungprotectiveventilationstrategies that truly make a difference when every second counts. The #HAMILTONT1 has our backs, from the initial 911 call, all the way through critical care transport (CCT), and beyond. Let’s come together to make a real impact with the care we provide. ???? I’m really looking forward to sharing, learning, and sparking conversations with you all. Let’s make #prehospitalcare even better, together! Swing by booth 14; let’s chat and change the future! March 27th & 28th 2024 ?? #EMSrevolution #GEMSA2024 #HAMILTONT1 #ParamedicLife #FireRescue #EmergencyMedicine #GradyEMS

How can Digital Health Tools (DHTs) improve clinical trials for patients? Join us at SCOPE this week. #ScopeSummit #clinicaltrials #digital #digitalhealth #digitalhealthinnovation #patients #patientengagement

On their Q124 earnings call, Sarepta noted that they anticipated a draft Elevidys label imminently.?They have since entered a quiet period. Does this mean an FDA decision is coming ahead of the official June 21 action date for Elevidys? Recall, Sarepta received accelerated approval for Elevidys close to a year ago (June 2023), but has asked FDA for full approval and a label expansion based, in part, on data from EMBARK as well as ENVISION, a study conducted in older, non-ambulatory patients with Duchenne. Three label variables are at play, making for a combination lock of potential outcomes when FDA makes its announcement: 1. The current accelerated label is for walking Duchenne patients (ambulatory) but Sarepta also wants approval in patients who are no longer walking. 2. The current accelerated approval label covers patients ages 4-5 only, whereas Sarepta wants approval without age restrictions. 3. Regardless of age or ambulatory status, Sarepta also wants conversion to a full approval for all Duchenne populations. Sarepta isn’t shy about asking for approval where they do not have clear data.?This means whatever decision FDA makes, it’s likely to be mosaic and not binary. Stay tuned, the answers could come at any point in the next six weeks leading up to June 21, but all indications point to the sooner side of that window. #sarepta #duchenne #elevidys #genetherapy #cgt #acceleratedapproval #fda #petermarks #raredisease

#InTheNews At HLTH USA recently, Carrum stood out amongst scores of digital health companies, thanks to our single-minded focus on lowering the cost of specialty care while improving quality. Carrum Founder and CEO Sach Jain spoke with Arundhati Parmar, Editor-in-Chief of MedCity News, about launching value-based substance use treatment — and how we’re doing it differently. “The area of substance use is full of fraud and abuse because 1), there are organizations that are not well set up, but it’s an episode that pays a lot of money and whether the member is actually getting better or not, they are discharged, and after a few days, weeks they come back and then you do the whole thing all over again,” Jain charged. “So this is called washing machine model — wash and repeat — and then you keep on making money on the same patient. So by identifying the organizations that first of all have the right quality of care for these episodes and then making them accountable for the care they’re delivering, that’s what makes this model sustain sobriety.” Read more: https://lnkd.in/gj2khpAQ #hlth2024 #hlth #substanceuse #valuebasedcare #carrumhealth

Breaking News: Blue Earth Diagnostics, Inc. welcomes proposed changes announced on July 10, 2024 by the Centers for Medicare & Medicaid Services’ (CMS) for Hospital Outpatient Prospective Payment System (OPPS) Rule. Blue Earth Diagnostics has been a pioneer in championing discussions with CMS to secure this rule change. This proposed rule is designed to improve payment for diagnostic radiopharmaceuticals that have lost, or will lose, their Transitional Pass-Through payment status. Upon passage, the updated rule would provide more equitable and dependable patient access to advanced imaging. Read more about Blue Earth Diagnostics and the proposed CMS update at https://lnkd.in/eYfkG7DD #Radiopharmaceuticals #PharmaNews #PatientAccess

Today on #WorldSickleCellDay, we stand united under the theme "Hope Through Progress: Advancing Sickle Cell Care Globally." At #WACCBIP, we're committed to driving research and innovations to enhance care and bring hope to patients worldwide. Together, we can make a difference! #WACCBIPis10